Dr. Wingo Discusses Neoadjuvant Chemotherapy in Ovarian Cancer

Shana Wingo, MD
Published: Thursday, May 17, 2018



Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the use of neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Although there has not been many new surgical advancements in the treatment of ovarian cancer in the last year, there has been an uptake of neoadjuvant chemotherapy. Wingo says that many patients do not see a gynecologic oncologist before they start their therapy, so many surgeons administer chemotherapy, perfom the surgery, and then follow-up themselves.

The adoption of neoadjuvant chemotherapy has caused a paradigm shift, Wingo says. Previously, upfront debulking was often used in lieu of neoadjuvant therapy. Wingo says that she feels less apprehensive about bypassing upfront debulking as more data come out in support of neoadjuvant chemotherapy. This paradigm shift may be a very positive one for patients with ovarian cancer, she concludes.


Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the use of neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Although there has not been many new surgical advancements in the treatment of ovarian cancer in the last year, there has been an uptake of neoadjuvant chemotherapy. Wingo says that many patients do not see a gynecologic oncologist before they start their therapy, so many surgeons administer chemotherapy, perfom the surgery, and then follow-up themselves.

The adoption of neoadjuvant chemotherapy has caused a paradigm shift, Wingo says. Previously, upfront debulking was often used in lieu of neoadjuvant therapy. Wingo says that she feels less apprehensive about bypassing upfront debulking as more data come out in support of neoadjuvant chemotherapy. This paradigm shift may be a very positive one for patients with ovarian cancer, she concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x